Previous 10 | Next 10 |
2024-03-06 17:20:06 ET More on Lumos Pharma Lumos Pharma, Inc. 2023 Q3 - Results - Earnings Call Presentation Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for...
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results ...
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34 th Annual...
2024-01-04 16:17:52 ET More on Lumos Pharma Lumos stock rockets nearly 100% in after-hours trading on study updates Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma For further details see: Lumos Pharma promote...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (C...
AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to disc...
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35 th Annual Healthcare Conference being held Nov...
2023-11-08 10:00:55 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Durect, Lumos Pharma among healthcare movers
Lumos Pharma Inc. (LUMO) is expected to report $-1.1 for Q3 2023
2023-11-07 17:22:37 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript Lumos stock rockets nearly 100% in after-hours trading on study updates Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lum...
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...